Cargando…

Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1

Mutations in polymerase ε (POLE) confer favorable prognosis and outcomes in various cancer types, but their role in non-small cell lung cancer (NSCLC) is unknown. Utilizing the data of 513 patients with adenocarcinoma (LUAD) and 497 patients with squamous cell carcinoma (LUSC) from The Cancer Genome...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Liang, Ruiz, Jimmy, O’Neill, Stacey S., Grant, Stefan C., Petty, W. Jeffrey, Yang, Meng, Chen, Kexin, Topaloglu, Umit, Pasche, Boris, Zhang, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897927/ https://www.ncbi.nlm.nih.gov/pubmed/29650000 http://dx.doi.org/10.1186/s12943-018-0832-y

Ejemplares similares

SMARCA4 mutations in KRAS‐mutant lung adenocarcinoma: a multi‐cohort analysis
por: Liu, Liang, et al.
Publicado: (2020)

Natural language processing and recurrent network models for identifying genomic mutation-associated cancer treatment change from patient progress notes
por: Guan, Meijian, et al.
Publicado: (2019)

High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations
por: Wang, Qinghua, et al.
Publicado: (2020)

Mesonephric Adenocarcinoma of the Vagina Harboring TP53 Mutation
por: Lee, Hyunjee, et al.
Publicado: (2022)

Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations
por: Zhang, Wenjing, et al.
Publicado: (2022)

Metachronous primary lung adenocarcinomas harboring distinct KRAS mutations
por: Hu, Yan, et al.
Publicado: (2020)

Mutant Proteomics of Lung Adenocarcinomas Harboring Different EGFR Mutations
por: Nishimura, Toshihide, et al.
Publicado: (2020)

Assessment of POLE and POLD1 mutations as prognosis and immunotherapy biomarkers for stomach adenocarcinoma
por: Zhu, Mingyu, et al.
Publicado: (2022)

Identification of CD37, cystatin A, and IL-23A gene expression in association with brain metastasis: analysis of a prospective trial
por: Dohm, Ammoren, et al.
Publicado: (2019)

Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation
por: Wen, Lei, et al.
Publicado: (2022)

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations
por: Li, Teng, et al.
Publicado: (2021)

A tale of three subspecialties: Diagnosis recording patterns are internally consistent but Specialty-Dependent
por: Diaz-Garelli, Jose-Franck, et al.
Publicado: (2019)

Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages
por: Yang, Meng, et al.
Publicado: (2017)

Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations
por: Chen, R.-L., et al.
Publicado: (2017)

Overall survival in patients with lung adenocarcinoma harboring “niche” mutations: an observational study
por: Aramini, Beatrice, et al.
Publicado: (2020)

Complete Response to Pembrolizumab in Advanced Colon Cancer Harboring Somatic POLE F367S Mutation with Microsatellite Stability Status: A Case Study
por: Chen, Jianxin, et al.
Publicado: (2021)

PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed
por: Zhang, Pei, et al.
Publicado: (2017)

Phenotype of POLE-mutated endometrial cancer
por: Imboden, Sara, et al.
Publicado: (2019)

Metastatic Lung Adenocarcinoma Harboring an EGFR-Activating Mutation in a Heart Transplant Recipient
por: Zambrano Mendoza, Elizabeth, et al.
Publicado: (2017)

Impact of Radiotherapy Pattern on the Prognosis of Stage IV Lung Adenocarcinomas Harboring EGFR Mutations
por: Zhang, Yingyun, et al.
Publicado: (2021)

A Naive Lung Adenocarcinoma Harboring G1269A ALK Resistance Mutation
por: Trabelsi-Grati, Olfa, et al.
Publicado: (2020)

Effect of thoracic radiotherapy dose on the prognosis of advanced lung adenocarcinoma harboring EGFR mutations
por: Qin, Hongyue, et al.
Publicado: (2022)

Mutant POLQ and POLZ/REV3L DNA polymerases may contribute to the favorable survival of patients with tumors with POLE mutations outside the exonuclease domain
por: Huang, Fangjin, et al.
Publicado: (2020)

POLE somatic mutations in advanced colorectal cancer
por: Guerra, Joana, et al.
Publicado: (2017)

Interpretation of somatic POLE mutations in endometrial carcinoma
por: León‐Castillo, Alicia, et al.
Publicado: (2020)

POLE/POLD1 mutation and tumor immunotherapy
por: Ma, Xiaoting, et al.
Publicado: (2022)

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene
por: Tanaka, Hisashi, et al.
Publicado: (2012)

Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations
por: Gao, Yuan, et al.
Publicado: (2017)

The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
por: Wu, Shang-Gin, et al.
Publicado: (2020)

Predisposition to Lung Adenocarcinoma in a Family Harboring the Germline EGFR V843I Mutation
por: Ohtsuka, Kouki, et al.
Publicado: (2019)

Clinicopathological and mutational analyses of colorectal cancer with mutations in the POLE gene
por: Hino, Hitoshi, et al.
Publicado: (2019)

The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations
por: Liu, Chien-Ying, et al.
Publicado: (2017)

Dissecting intratumoral myeloid cell plasticity by single cell RNA‐seq
por: Song, Qianqian, et al.
Publicado: (2019)

Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report
por: Kuwata, Taiji, et al.
Publicado: (2016)

Histological evolution from primary lung adenocarcinoma harboring EGFR mutation to high‐grade neuroendocrine carcinoma
por: Zhao, Jikai, et al.
Publicado: (2017)

Targeted Next-Generation Sequencing Analysis Predicts the Recurrence in Resected Lung Adenocarcinoma Harboring EGFR Mutations
por: Kim, In Ae, et al.
Publicado: (2021)

Durable Response to Chemoimmunotherapy of a Lung Adenocarcinoma Harboring a MET Exon 14 Skipping Mutation
por: Nitta, Naohiro, et al.
Publicado: (2023)

Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations
por: Tarabay, Anthony, et al.
Publicado: (2023)

Internal hemorrhoid harboring adenocarcinoma: A case report
por: Caparelli, Michael L, et al.
Publicado: (2021)

Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer
por: Church, David N., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jn5ricsms4le2qgqs2mn0eakle